Advanced Search

Subscribe to a Global-Regulation Premium Membership Today!

We are constantly working to improve the site, and to add more laws to our database. If you are receiving value from using our site please consider signing up for a subscription to support the site and to get many additional benefits for you.

Key Benefits:

  • Unlimited Searches
  • Weekly Updates on New Laws
  • Access to 5,345,848 Global Laws from 110 Countries
  • View the Original Law Side-by-Side with the Translation
  • No Ads

Subscribe Now for only USD$40 per month.

(You can close this ad by clicking anywhere on the page.)

Corrigendum To The Relative Alregime Of 19/2015 January 19, 2015 # Determines New Listings And Price As A Result Of New Therapeutic Indications Of A Medicinal Product For Human Use "simponi (Golimumab). (Resolution No. 130/2015).

Original Language Title: Rettifica della determina n. 19/2015 del 19 gennaio 2015 relativa alregime di rimborsabilita' e prezzo a seguito di nuove indicazioniterapeutiche del medicinale per uso umano «Simponi» (golimumab).(Determina n. 130/2015).

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
The DIRECTOR-GENERAL having regard to determining # 19/2015 of January 19, 2015 concerning a medicinal product for human use SIMPONI (golimumab) published in the official journal-General series-# 22 of January 28, 2015; Considered the documentation to this Office;
Correction: in art. 2 (for the purpose of Classification) where it is written: for the therapeutic indications rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist; Read: therapeutic indications for rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist, internist;
Rome, February 11, 2015 Director General: Pani